ResearchWorks Archive

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Files in this item

This item appears in the following Collection(s)

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics